- Results from ACTIV-3b study using ZYESAMI for treatment of hospitalized patients with Covid-19 are expected in 1st half of 2022. NDA approval expected in 2nd half of 2022 with successful data.
- Initiation of phase 3 study using NRX-101 for treatment of hospitalized bipolar depression patients with suicidal ideation expected 1st half of 2022. If successful, NDA filing expected 2023.
- With positive phase 2/3 data of BriLife in Covid-19, NDA filing expected 2nd half of 2022.
- NRx Pharmaceuticals had $38.9 million in cash as of September 30, 2021, but raised $25 million in a private placement agreement in January of 2022.
For further details see:
NRx Pharmaceuticals: Potential For First In Bipolar Depression Suicidal Ideation Treatment, Along As Covid-19 Play